Driehaus Capital Management LLC Has $11.10 Million Stock Position in Ascendis Pharma A/S (NASDAQ:ASND)

Driehaus Capital Management LLC lowered its position in shares of Ascendis Pharma A/S (NASDAQ:ASND) by 18.9% during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 81,396 shares of the biotechnology company’s stock after selling 18,924 shares during the quarter. Driehaus Capital Management LLC owned 0.14% of Ascendis Pharma A/S worth $11,101,000 as of its most recent SEC filing.

Other large investors have also made changes to their positions in the company. Private Ocean LLC purchased a new position in Ascendis Pharma A/S during the 1st quarter worth approximately $36,000. GAMMA Investing LLC raised its position in Ascendis Pharma A/S by 52.0% during the first quarter. GAMMA Investing LLC now owns 298 shares of the biotechnology company’s stock valued at $45,000 after buying an additional 102 shares during the period. Bessemer Group Inc. lifted its stake in Ascendis Pharma A/S by 61.0% in the 1st quarter. Bessemer Group Inc. now owns 876 shares of the biotechnology company’s stock worth $132,000 after acquiring an additional 332 shares in the last quarter. Barometer Capital Management Inc. purchased a new stake in Ascendis Pharma A/S in the 4th quarter worth about $126,000. Finally, Searle & CO. acquired a new stake in Ascendis Pharma A/S during the 2nd quarter worth about $205,000.

Ascendis Pharma A/S Trading Down 1.9 %

ASND stock opened at $144.62 on Monday. The business’s 50 day moving average is $134.39 and its 200-day moving average is $136.36. The firm has a market cap of $8.42 billion, a P/E ratio of -15.05 and a beta of 0.63. Ascendis Pharma A/S has a 1-year low of $85.29 and a 1-year high of $161.00.

Ascendis Pharma A/S (NASDAQ:ASND) last released its quarterly earnings results on Tuesday, September 3rd. The biotechnology company reported ($2.05) EPS for the quarter, missing analysts’ consensus estimates of ($1.54) by ($0.51). The firm had revenue of $38.75 million during the quarter, compared to analyst estimates of $94.74 million. Ascendis Pharma A/S had a negative net margin of 154.18% and a negative return on equity of 16,574.15%. Sell-side analysts forecast that Ascendis Pharma A/S will post -7.15 EPS for the current year.

Analysts Set New Price Targets

A number of analysts have recently issued reports on the stock. Citigroup increased their price target on shares of Ascendis Pharma A/S from $178.00 to $207.00 and gave the stock a “buy” rating in a research report on Tuesday, September 17th. Jefferies Financial Group raised their price target on Ascendis Pharma A/S from $174.00 to $196.00 and gave the stock a “buy” rating in a research note on Tuesday, August 13th. Oppenheimer reaffirmed an “outperform” rating and issued a $190.00 price objective (up previously from $180.00) on shares of Ascendis Pharma A/S in a research note on Tuesday, September 17th. Cantor Fitzgerald reissued an “overweight” rating and issued a $170.00 price objective on shares of Ascendis Pharma A/S in a research note on Monday, September 16th. Finally, Evercore ISI boosted their target price on shares of Ascendis Pharma A/S from $191.00 to $205.00 and gave the stock an “outperform” rating in a research report on Tuesday, September 17th. Two research analysts have rated the stock with a hold rating and thirteen have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $195.00.

Ascendis Pharma A/S Profile

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.